Legend Biotech (LEGN) Cash & Equivalents (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Cash & Equivalents data on file, last reported at $646.4 million in Q1 2026.

• Quarterly Cash & Equivalents fell 35.71% year-over-year to $646.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $646.4 million (down 35.71% YoY) and the FY2025 annual result came in at $901.9 million, up 214.58% from the prior year.
• Cash & Equivalents retreated to $646.4 million in Q1 2026, from $901.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.3 billion in Q2 2023 to a low of $266.6 million in Q2 2025.
• A 5-year average of $854.3 million and a median of $901.9 million in 2025 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 214.58% in 2025, down 78.75% in 2025.
• Tracing LEGN's Cash & Equivalents over 5 years: stood at $786.0 million in 2022, then jumped by 62.55% to $1.3 billion in 2023, then tumbled by 77.56% to $286.7 million in 2024, then jumped by 214.58% to $901.9 million in 2025, then fell by 28.33% to $646.4 million in 2026.
• The last three Cash & Equivalents figures came in at $646.4 million (Q1 2026), $901.9 million (Q4 2025), and $278.9 million (Q3 2025), per Business Quant data.